Review Article
The effects of melatonin on signaling pathways and molecules involved in glioma
Foroogh Neamati,
Zatollah Asemi,
Foroogh Neamati
Department of Microbiology, Kashan University of Medical Sciences, Kashan, 87159-88141 I.R. Iran
Search for more papers by this authorCorresponding Author
Zatollah Asemi
Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, 87159-88141 I.R. Iran
Correspondence and reprints: [email protected]Search for more papers by this author
Foroogh Neamati,
Zatollah Asemi,
Foroogh Neamati
Department of Microbiology, Kashan University of Medical Sciences, Kashan, 87159-88141 I.R. Iran
Search for more papers by this authorCorresponding Author
Zatollah Asemi
Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, 87159-88141 I.R. Iran
Correspondence and reprints: [email protected]Search for more papers by this authorAbstract
Glioblastoma is one of the most common brain tumors with high invasion and malignancy. Despite extensive research in this area and the use of new and advanced therapies, the survival rate in this disease is very low. In addition, resistance to treatment has also been observed in this disease. One of the reasons for rapid progression and failure in treatment for this disease is the presence of a class of cells with high proliferation and high differentiation, a class called glioblastoma stem-like cells shown as being the source of glioblastoma tumors. It has been reported that several oncogenes are expressed in this disease. One important issue in recognizing the pathogenesis of this disease, and which could improve the treatment process, is the identification of involved oncogenes as well as molecules that affect the reduction of the expression of these oncogenes. Melatonin regulates the biological rhythm and inhibits the proliferation of malignant glioma cells due to antioxidant and anti-apoptotic effects. Melatonin has been considered in biological processes and in signaling pathways involved in the development of glioma. The aim of this review is to investigate the effects of melatonin on signaling pathways and molecules involved in the progression of glioma.
References
- 1Munksgaard Thoren M., Chmielarska Masoumi K., Krona C. et al. Integrin alpha10, a novel therapeutic target in glioblastoma, regulates cell migration, proliferation, and survival. Cancers (2019) 11 E587.
- 2Masoudi M.S., Mehrabian E., Mirzaei H. MiR-21: a key player in glioblastoma pathogenesis. J. Cell. Biochem. (2018) 119 1285–1290.
- 3Li Y.P., Dai W.M., Huang Q. et al. Effects of microRNA-26b on proliferation and invasion of glioma cells and related mechanisms.. Mol. Med. Rep. (2017) 16 4165–4170.
- 4Saadatpour L., Fadaee E., Fadaei S. et al. Glioblastoma: exosome and microRNA as novel diagnosis biomarkers. Cancer Gene Ther. (2016) 23 415–418.
- 5Cheng T., Xu Y. Effects of enhancer of zeste homolog 2 (EZH2) expression on brain glioma cell proliferation and tumorigenesis. Med. Sci. Monit. (2018) 24 7249–7255.
- 6Kleihues P., Aguzzi A., Ohgaki H. Genetic and environmental factors in the etiology of human brain tumors. Toxicol. Lett. (1995) 82 601–605.
- 7Melin B.S., Barnholtz-Sloan J.S., Wrensch M.R. et al. Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors. Nat. Genet. (2017) 49 789.
- 8Farrell C.J., Plotkin S.R. Genetic causes of brain tumors: neurofibromatosis, tuberous sclerosis, von Hippel-Lindau, and other syndromes. Neurol. Clin. (2007) 25 925–946.
- 9Louis D.N. Molecular pathology of malignant gliomas. Annu. Rev. Pathol. Mech Dis. (2006) 1 97–117.
- 10Minaei S.E., Khoei S., Khoee S., Vafashoar F., Mahabadi V.P. In vitro anti-cancer efficacy of multi-functionalized magnetite nanoparticles combining alternating magnetic hyperthermia in glioblastoma cancer cells. Mater. Sci. Eng. C Mater. Biol. Appl. (2019) 101 575–587.
- 11D'Alessio A., Proietti G., Sica G., Scicchitano B.M.J.C. Pathological and molecular features of glioblastoma and its peritumoral tissue, Cancers (2019) 11 469.
- 12Martín V., Sanchez-Sanchez A.M., Puente-Moncada N. et al. Involvement of autophagy in melatonin-induced cytotoxicity in glioma-initiating cells. J. Pineal Res. (2014) 57 308–316.
- 13Aldaz B., Sagardoy A., Nogueira L. et al. Involvement of miRNAs in the differentiation of human glioblastoma multiforme stem-like cells. PLoS ONE (2013) 8 e77098.
- 14Chen X., Hao A., Li X. et al. Melatonin inhibits tumorigenicity of glioblastoma stem-like cells via the AKT-EZH2-STAT3 signaling axis. J. Pineal Res. (2016) 61 208–217.
- 15Jackson M., Hassiotou F., Nowak A. Glioblastoma stem-like cells: at the root of tumor recurrence and a therapeutic target. Carcinogenesis (2014) 36 177–185.
- 16Hou Z., Yang J., Wang H., Liu D., Zhang H. A potential prognostic gene signature for predicting survival for glioblastoma patients. Biomed. Res. Int. (2019) 2019 9506461.
- 17Skaga E., Skaga I.O., Grieg Z., Sandberg C.J., Langmoen I.A., Vik-Mo E.O. The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy. J. Cancer Res. Clin. Oncol. (2019) 145(6): 1495–1507
- 18Ji P., Zhou X., Liu Q., Fuller G.N., Phillips L.M., Zhang W. Driver or passenger effects of augmented c-Myc and Cdc20 in gliomagenesis. Oncotarget. (2016) 7 23521–23529.
- 19González A., Martínez-Campa C., Mediavilla M.D. et al. Inhibitory effects of melatonin on sulfatase and 17β-hydroxysteroid dehydrogenase activity and expression in glioma cells. Oncol. Rep. (2010) 23 1173–1178.
- 20Shafabakhsh R., Reiter R.J., Mirzaei H. Melatonin: a new inhibitor agent for cervical cancer treatment. J. Cell. Physiol. (2019) 234 21670–21682.
- 21Tijmes M., Pedraza R., Valladares L. Melatonin in the rat testis: evidence for local synthesis. Steroids (1996) 61 65–68.
- 22Vacas M.I., Del Zar M.D.l.M., Martinuzzo M., Cardinali D.P. Binding sites for [3H]-melatonin in human platelets. J. Pineal Res. (1992) 13 60–65.
- 23Carrillo-Vico A., Calvo J.R., Abreu P. et al. Evidence of melatonin synthesis by human lymphocytes and its physiological significance: possible role as intracrine, autocrine, and/or paracrine substance. FASEB J. (2004) 18 537–539.
- 24Liu Y.J., Zhuang J., Zhu H.Y., Shen Y.X., Tan Z.L., Zhou J.N. Cultured rat cortical astrocytes synthesize melatonin: absence of a diurnal rhythm. J. Pineal Res. (2007) 43 232–238.
- 25Skinner D.C., Malpaux B. High melatonin concentrations in third ventricular cerebrospinal fluid are not due to Galen vein blood recirculating through the choroid plexus. Endocrinology (1999) 140 4399–4405.
- 26Adachi A., Natesan A.K., Whitfield-Rucker M.G., Weigum S.E., Cassone V.M. Functional melatonin receptors and metabolic coupling in cultured chick astrocytes. Glia (2002) 39 268–278.
- 27Kong P.-J., Byun J.-S., Lim S.-Y. et al. Melatonin induces Akt phosphorylation through melatonin receptor-and PI3K-dependent pathways in primary astrocytes. Korean J. Physiol. Pharmacol. (2008) 12 37–41.
- 28Anderson G., Reiter R.J. Glioblastoma: role of mitochondria N-acetylserotonin/melatonin ratio in mediating effects of miR-451 and aryl hydrocarbon receptor and in coordinating wider biochemical changes. Int. J. Tryptophan Res. (2019) 12 1178646919855942.
- 29Lee H., Lee H.J., Jung J.H., Shin E.A., Kim S.H. Melatonin disturbs SUMOylation-mediated crosstalk between c-Myc and nestin via MT1 activation and promotes the sensitivity of paclitaxel in brain cancer stem cells. J. Pineal Res. (2018) 65 e12496.
- 30Tamtaji O.R., Mirhosseini N., Reiter R.J., Behnamfar M., Asemi Z. Melatonin and pancreatic cancer: current knowledge and future perspectives. J. Cell. Physiol. (2019) 234 5372–5378.
- 31Zheng X., Pang B., Gu G. et al. Melatonin inhibits glioblastoma stem-like cells through suppression of EZH2-NOTCH1 signaling axis. Int. J. Biol. Sci. (2017) 13 245–253.
- 32Xu C.-S., Wang Z.-F., Huang X.-D., Dai L.-M., Cao C.-J., Li Z.-Q.J.J.O.T.M. Involvement of ROS-alpha v beta 3 integrin-FAK/Pyk2 in the inhibitory effect of melatonin on U251 glioma cell migration and invasion under hypoxia. J. Transl. Med. (2015) 13 95.
- 33Sung G.J., Kim S.H., Kwak S. et al. Inhibition of TFEB oligomerization by co-treatment of melatonin with vorinostat promotes the therapeutic sensitivity in glioblastoma and glioma stem cells. J. Pineal Res. (2019) 66 e12556.
- 34Franco D.G., Moretti I.F., Marie S.K.N. Mitochondria transcription factor a: a putative target for the effect of melatonin on U87MG malignant glioma cell line. Molecules (Basel, Switzerland) (2018) 23(5). pii: E1129.
- 35Jin F., Zhao L., Zhao H.Y. et al. Comparison between cells and cancer stem-like cells isolated from glioblastoma and astrocytoma on expression of anti-apoptotic and multidrug resistance-associated protein genes. Neuroscience (2008) 154 541–550.
- 36McConnell D., McGreevy J., Williams M., Litofsky N.J.M. Do anti-oxidants vitamin D3, melatonin, and alpha-lipoic acid have synergistic effects with temozolomide on cultured glioblastoma cells?. Medicines (Basel) (2018) 5 58.
- 37Wang J., Hao H., Yao L. et al. Melatonin suppresses migration and invasion via inhibition of oxidative stress pathway in glioma cells. J. Pineal Res. (2012) 53 180–187.
- 38Martin V., Herrera F., Carrera-Gonzalez P. et al. Intracellular signaling pathways involved in the cell growth inhibition of glioma cells by melatonin. Can. Res. (2006) 66 1081–1088.
- 39Martín V., Herrera F., Garcia-Santos G. et al. Involvement of protein kinase C in melatonin's oncostatic effect in C6 glioma cells.. J. Pineal Res. (2007) 43 239–244.
- 40Ramachandran R.K., Sorensen M.D., Aaberg-Jessen C., Hermansen S.K., Kristensen B.W. Expression and prognostic impact of matrix metalloproteinase-2 (MMP-2) in astrocytomas. PLoS ONE (2017) 12 e0172234.
- 41Zhang H., Ma Y., Wang H., Xu L., Yu Y. MMP-2 expression and correlation with pathology and MRI of glioma. Oncol. Lett. (2019) 17 1826–1832.
- 42Huang X.-D., Wang Z.-F., Dai L.-M., Li Z.-Q.J.A.P.J.O.C.P. Microarray analysis of the hypoxia-induced gene expression profile in malignant C6 glioma cells. Asian Pac. J. Cancer Prev. (2012) 13 4793–4799.
- 43Zhang Y., Liu Q., Wang F. et al. Melatonin antagonizes hypoxia-mediated glioblastoma cell migration and invasion via inhibition of HIF-1α. J. Pineal Res. (2013) 55 121–130.
- 44Lipinski C.A., Tran N.L., Menashi E. et al. The tyrosine kinase pyk2 promotes migration and invasion of glioma cells. Neoplasia (New York, NY). (2005) 7 435–445.
- 45Xu C.-S., Wang Z.-F., Dai L.-M. et al. Induction of proline-rich tyrosine kinase 2 activation-mediated C6 glioma cell invasion after anti-vascular endothelial growth factor therapy. J. Transl. Med. (2014) 12 148.
- 46Kim K.J., Choi J.S., Kang I., Kim K.W., Jeong C.H., Jeong J.W. Melatonin suppresses tumor progression by reducing angiogenesis stimulated by HIF-1 in a mouse tumor model. J. Pineal Res. (2013) 54 264–270.
- 47Park S.Y., Jang W.J., Yi E.Y. et al. Melatonin suppresses tumor angiogenesis by inhibiting HIF-1alpha stabilization under hypoxia. J. Pineal Res. (2010) 48 178–184.
- 48Fagnocchi L., Zippo A. Multiple roles of MYC in integrating regulatory networks of pluripotent stem cells. Front. Cell Dev. Biol. (2017) 5 7.
- 49Ishida C.T., Shu C., Halatsch M.E. et al. Mitochondrial matrix chaperone and c-myc inhibition causes enhanced lethality in glioblastoma. Oncotarget. (2017) 8 37140–37153.
- 50Matsuda Y., Ishiwata T., Yoshimura H., Hagio M., Arai T. Inhibition of nestin suppresses stem cell phenotype of glioblastomas through the alteration of post-translational modification of heat shock protein HSPA8/HSC71. Cancer Lett. (2015) 357 602–611.
- 51Qu J., Rizak J.D., Li X., Li J., Ma Y. Melatonin treatment increases the transcription of cell proliferation-related genes prior to inducing cell death in C6 glioma cells in vitro. Oncol. Lett. (2013) 6 347–352.
- 52Piras F., Ionta M., Lai S. et al. Nestin expression associates with poor prognosis and triple negative phenotype in locally advanced (T4) breast cancer. Eur. J. Histochem.. (2011) 55 e39.
- 53Ahmad F., Patrick S., Sheikh T. et al. Telomerase reverse transcriptase (TERT) - enhancer of zeste homolog 2 (EZH2) network regulates lipid metabolism and DNA damage responses in glioblastoma. J. Neurochem. (2017) 143 671–683.
- 54Wang J., Cheng P., Pavlyukov M.S. et al. Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2. J. Clin. Investig. (2017) 127 3075–3089.
- 55Uribe D., Torres A., Rocha J.D. et al. Multidrug resistance in glioblastoma stem-like cells: role of the hypoxic microenvironment and adenosine signaling. Mol. Aspects Med. (2017) 55 140–151.
- 56Drean A., Rosenberg S., Lejeune F.X. et al. ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma. J. Neurooncol. (2018) 138 479–486.
- 57Rama A.R., Alvarez P.J., Madeddu R., Aranega A. ABC transporters as differentiation markers in glioblastoma cells. Mol. Biol. Rep. (2014) 41 4847–4851.
- 58Martin V., Sanchez-Sanchez A.M., Herrera F. et al. Melatonin-induced methylation of the ABCG2/BCRP promoter as a novel mechanism to overcome multidrug resistance in brain tumour stem cells. Br. J. Cancer (2013) 108 2005–2012.
- 59Daniele S., Pietrobono D., Costa B. et al. Bax activation blocks self-renewal and induces apoptosis of human glioblastoma stem cells. ACS Chem. Neurosci. (2018) 9 85–99.
- 60Capper D., Gaiser T., Hartmann C. et al. Stem-cell-like glioma cells are resistant to TRAIL/Apo2L and exhibit down-regulation of caspase-8 by promoter methylation. Acta Neuropathol. (2009) 117 445–456.
- 61Roth W., Isenmann S., Naumann U. et al. Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. Biochem. Biophys. Res. Comm. (1999) 265 479–483.
- 62Walczak H., Bouchon A., Stahl H., Krammer P.H. Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells. Can. Res. (2000) 60 3051–3057.
- 63Yoshida T., Azuma H., Aihara K.-I. et al. Vascular smooth muscle cell proliferation is dependent upon upregulation of mitochondrial transcription factor A (mtTFA) expression in injured rat carotid artery.. Atherosclerosis (2005) 178 39–47.
- 64Jiang J., Yang J., Wang Z., Wu G., Liu F.J.O.R. TFAM is directly regulated by miR-23b in glioma. Oncol. Rep. (2013) 30 2105–2110.
- 65Tu M., Cai L., Zheng W., Su Z., Chen Y., Qi S.J.M.M.R. CD164 regulates proliferation and apoptosis by targeting PTEN in human glioma. Mol. Med. Rep. (2017) 15 1713–1721.
- 66Wick W., Furnari F.B., Naumann U., Cavenee W.K., Weller M. PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis. Oncogene (1999) 18 3936–3943.
- 67Carico C., Nuño M., Mukherjee D. et al. Loss of PTEN is not associated with poor survival in newly diagnosed glioblastoma patients of the temozolomide era. PLoS ONE (2012) 7 e33684.
- 68Gu J.-J., Fan K.-C., Zhang J.-H., Chen H.-J., Wang S.-S.J.I.J.O.M.M. Suppression of microRNA-130b inhibits glioma cell proliferation and invasion, and induces apoptosis by PTEN/AKT signaling. Int. J. Mol. Med. (2018) 41 284–292.
- 69Jang H., Lee O.H., Lee Y. et al. Melatonin prevents cisplatin-induced primordial follicle loss via suppression of PTEN/AKT/FOXO3a pathway activation in the mouse ovary. J. Pineal Res. (2016) 60 336–347.
- 70Ma H., Wang Z., Hu L. et al. The melatonin-MT1 receptor axis modulates tumor growth in PTEN-mutated gliomas.. Biochem. Biophys. Res. Commun. (2018) 496 1322–1330.
- 71Tan X., Wang S., Zhu L. et al. cAMP response element-binding protein promotes gliomagenesis by modulating the expression of oncogenic microRNA-23a. Proc. Natl Acad. Sci. USA (2012) 109 15805–15810.
- 72Xue K., Yang J., Hu J., Liu J., Li X. MicroRNA-133b expression associates with clinicopathological features and prognosis in glioma. Artif. Cells Nanomed. Biotechnol. (2018) 46 815–818.
- 73Tavakolizadeh J., Roshanaei K., Salmaninejad A. et al. MicroRNAs and exosomes in depression: potential diagnostic biomarkers. J. Cell. Biochem. (2018) 119 3783–3797.
- 74Mirzaei H., Ferns G.A., Avan A., Mobarhan M.G. Cytokines and MicroRNA in coronary artery disease. Adv. Clin. Chem. (2017) 82 47–70.
- 75Gholamin S., Mirzaei H. GD2-targeted immunotherapy and potential value of circulating microRNAs in neuroblastoma. J. Cell. Physiol. (2018) 233 866–879.
- 76Keshavarzi M., Sorayayi S., Jafar Rezaei M. et al. MicroRNAs-based imaging techniques in cancer diagnosis and therapy. J. Cell. Biochem. (2017) 118 4121–4128.
- 77Liu Q., Liao F., Wu H., Cai T., Yang L., Fang J. Different expression of miR-29b and VEGFA in glioma. Artif. Cells Nanomed. Biotechnol. (2016) 44 1927–1932.
- 78Visani M., de Biase D., Marucci G. et al. Expression of 19 microRNAs in glioblastoma and comparison with other brain neoplasia of grades I-III. Mol. Oncol. (2014) 8 417–430.
- 79Chan X.H., Nama S., Gopal F. et al. Targeting glioma stem cells by functional inhibition of a prosurvival oncomiR-138 in malignant gliomas. Cell Rep. (2012) 2 591–602.
- 80Hardeland R. Interactions of melatonin and MicroRNAs. Biochem. Mol. Biol. J. (2018) 4(1) 7.
10.21767/2471-8084.100056 Google Scholar
- 81Ling N., Gu J., Lei Z. et al. microRNA-155 regulates cell proliferation and invasion by targeting FOXO3a in glioma. Oncol. Rep. (2013) 30 2111–2118.
- 82Gu J., Lu Z., Ji C. et al. Melatonin inhibits proliferation and invasion via repression of miRNA-155 in glioma cells. Biomed. Pharmacother. (2017) 93 969–975.
- 83Xu W., Liu M., Peng X. et al. miR-24-3p and miR-27a-3p promote cell proliferation in glioma cells via cooperative regulation of MXI1. Int. J. Oncol. (2013) 42 757–766.
- 84Mori F., Ferraiuolo M., Santoro R. et al. Multitargeting activity of miR-24 inhibits long-term melatonin anticancer effects. Oncotarget (2016) 7 20532.
- 85Haghighat N., Oblinger M.M., McCandless D.W. Cytoprotective effect of estrogen on ammonium chloride-treated C6-glioma cells. Neurochem. Res. (2004) 29 1359–1364.
- 86Yague J.G., Lavaque E., Carretero J., Azcoitia I., Garcia-Segura L.M. Aromatase, the enzyme responsible for estrogen biosynthesis, is expressed by human and rat glioblastomas. Neurosci. Lett. (2004) 368 279–284.
- 87Gonzalez A., Martinez-Campa C., Mediavilla M.D., Alonso-Gonzalez C., Sanchez-Barcelo E.J., Cos S. Inhibitory effects of pharmacological doses of melatonin on aromatase activity and expression in rat glioma cells. Br. J. Cancer (2007) 97 755–760.
- 88Grant S.G., Melan M.A., Latimer J.J., Witt-Enderby P.A. Melatonin and breast cancer: cellular mechanisms, clinical studies and future perspectives. Expert Rev. Mol. Med. (2009) 11 e5.
- 89Jung B., Ahmad N. Melatonin in cancer management: progress and promise. Can. Res. (2006) 66 9789–9793.
